rhil15 (PeproTech)
PeproTech is a verified supplier 
90
Structured Review
PeproTech
rhil15
Rhil15, supplied by PeproTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rhil15/rhil+7/pm39843734-753-49-53
Average 90 stars, based on 1 article reviews
Rhil15, supplied by PeproTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rhil15/rhil+7/pm39843734-753-49-53
Average 90 stars, based on 1 article reviews
rhil15 - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
Plasmid Preparation:Article Title: Development of a novel redirected T-cell-based adoptive immunotherapy targeting human telomerase reverse transcriptase for adult T-cell leukemia. Article Snippet: Department of Bioregulatory Medicine, Ehime University Graduate School of Medicine, Toon, Japan; Department of Cell Growth and Tumor Regulation, Ehime University Proteo-Medicine Research Center, Toon, Japan; Immune Therapy Program, Ontario Cancer Institute, Toronto, Canada; Department of Medical Oncology and Immunology, Nagoya City University School of Medical Sciences, Aichi, Japan; Center for Cell and Gene Therapy, Takara Bio Inc., Expressing:Article Title: Development of a novel redirected T-cell-based adoptive immunotherapy targeting human telomerase reverse transcriptase for adult T-cell leukemia. Article Snippet: Department of Bioregulatory Medicine, Ehime University Graduate School of Medicine, Toon, Japan; Department of Cell Growth and Tumor Regulation, Ehime University Proteo-Medicine Research Center, Toon, Japan; Immune Therapy Program, Ontario Cancer Institute, Toronto, Canada; Department of Medical Oncology and Immunology, Nagoya City University School of Medical Sciences, Aichi, Japan; Center for Cell and Gene Therapy, Takara Bio Inc., Construct:Article Title: Development of a novel redirected T-cell-based adoptive immunotherapy targeting human telomerase reverse transcriptase for adult T-cell leukemia. Article Snippet: Department of Bioregulatory Medicine, Ehime University Graduate School of Medicine, Toon, Japan; Department of Cell Growth and Tumor Regulation, Ehime University Proteo-Medicine Research Center, Toon, Japan; Immune Therapy Program, Ontario Cancer Institute, Toronto, Canada; Department of Medical Oncology and Immunology, Nagoya City University School of Medical Sciences, Aichi, Japan; Center for Cell and Gene Therapy, Takara Bio Inc., Isolation:Article Title: Development of a novel redirected T-cell-based adoptive immunotherapy targeting human telomerase reverse transcriptase for adult T-cell leukemia. Article Snippet: Department of Bioregulatory Medicine, Ehime University Graduate School of Medicine, Toon, Japan; Department of Cell Growth and Tumor Regulation, Ehime University Proteo-Medicine Research Center, Toon, Japan; Immune Therapy Program, Ontario Cancer Institute, Toronto, Canada; Department of Medical Oncology and Immunology, Nagoya City University School of Medical Sciences, Aichi, Japan; Center for Cell and Gene Therapy, Takara Bio Inc., Magnetic Cell Separation:Article Title: Development of a novel redirected T-cell-based adoptive immunotherapy targeting human telomerase reverse transcriptase for adult T-cell leukemia. Article Snippet: Department of Bioregulatory Medicine, Ehime University Graduate School of Medicine, Toon, Japan; Department of Cell Growth and Tumor Regulation, Ehime University Proteo-Medicine Research Center, Toon, Japan; Immune Therapy Program, Ontario Cancer Institute, Toronto, Canada; Department of Medical Oncology and Immunology, Nagoya City University School of Medical Sciences, Aichi, Japan; Center for Cell and Gene Therapy, Takara Bio Inc., Cell Culture:Article Title: Development of a novel redirected T-cell-based adoptive immunotherapy targeting human telomerase reverse transcriptase for adult T-cell leukemia. Article Snippet: Department of Bioregulatory Medicine, Ehime University Graduate School of Medicine, Toon, Japan; Department of Cell Growth and Tumor Regulation, Ehime University Proteo-Medicine Research Center, Toon, Japan; Immune Therapy Program, Ontario Cancer Institute, Toronto, Canada; Department of Medical Oncology and Immunology, Nagoya City University School of Medical Sciences, Aichi, Japan; Center for Cell and Gene Therapy, Takara Bio Inc., |